Samia Mora

Q: What Schools Are Affiliated With Samia Mora

Samia Mora is affiliated with the following schools: Stanford University, Harvard University

Samia Mora's AcademicInfluence.com Rankings

Samia Mora

Philosophy

#9146

World Rank

#12661

Historical Rank

Logic

#6137

World Rank

#7622

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Samia Mora's Degrees

Doctorate Medicine Stanford University

Why Is Samia Mora Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Samia Mora's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Discovery and Refinement of Loci Associated with Lipid Levels (2013) (2475)
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. (2007) (1547)
Physical Activity and Reduced Risk of Cardiovascular Events: Potential Mediating Mechanisms (2007) (961)
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease (2019) (933)
Common variants associated with plasma triglycerides and risk for coronary artery disease (2013) (767)
Marine n‐3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (2019) (572)
Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. (2012) (532)
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. (2014) (513)
Physical Activity Attenuates the Influence of FTO Variants on Obesity Risk: A Meta-Analysis of 218,166 Adults and 19,268 Children (2011) (508)
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med (2016) (489)
Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. (2003) (444)
Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women (2009) (443)
Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. (2006) (432)
Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events (2008) (399)
LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). (2007) (378)
Forty-Three Loci Associated with Plasma Lipoprotein Size, Concentration, and Cholesterol Content in Genome-Wide Analysis (2009) (345)
High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). (2012) (333)
Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. (2011) (306)
Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin) (2013) (303)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials (2018) (281)
A Multivariate Genome-Wide Association Analysis of 10 LDL Subfractions, and Their Response to Statin Treatment, in 1868 Caucasians (2014) (228)
High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy (2013) (225)
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? (2006) (216)
Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study (2004) (197)
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial (2010) (191)
Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. (2007) (189)
Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events (2014) (176)
Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients: A Meta-Analysis (2013) (174)
A Novel Protein Glycan Biomarker and Future Cardiovascular Disease Events (2014) (171)
Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. (2009) (170)
Lipoprotein(a) and risk of type 2 diabetes. (2010) (164)
Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) (2017) (163)
Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women (2010) (161)
Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. (2016) (159)
Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy: The Treating to New Targets (TNT) Study (2012) (157)
Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medi (2016) (151)
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. (2018) (148)
ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiova (2009) (136)
The use of high-sensitivity assays for C-reactive protein in clinical practice (2008) (135)
Exercise Blood Pressure and Future Cardiovascular Death in Asymptomatic Individuals (2010) (126)
AHA/ACCF [corrected] 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention (2009) (123)
Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III) (2014) (120)
Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women (2018) (115)
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM (2019) (111)
Lipoprotein Particles and Incident Type 2 Diabetes in the Multi-Ethnic Study of Atherosclerosis (2015) (110)
The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. (2009) (105)
Lipid biomarkers and long-term risk of cancer in the Women's Health Study. (2016) (105)
Enhanced Risk Assessment in Asymptomatic Individuals With Exercise Testing and Framingham Risk Scores (2005) (98)
Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol (2017) (96)
Lifestyle Interaction With Fat Mass and Obesity-Associated (FTO) Genotype and Risk of Obesity in Apparently Healthy U.S. Women (2011) (96)
Novel Protein Glycan Side-Chain Biomarker and Risk of Incident Type 2 Diabetes Mellitus (2015) (89)
Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. (2009) (86)
Additive Value of Immunoassay-Measured Fibrinogen and High-Sensitivity C-Reactive Protein Levels for Predicting Incident Cardiovascular Events (2006) (85)
Interaction of Body Mass Index and Framingham Risk Score in Predicting Incident Coronary Disease in Families (2005) (85)
Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. (2016) (83)
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial (2015) (78)
Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. (2007) (78)
The Metabolic Syndrome in Women (2006) (77)
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement (2022) (75)
Paradoxical Association of Lipoprotein Measures With Incident Atrial Fibrillation (2014) (71)
Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence: Prospective Data From the Women’s Health Study (2018) (69)
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. (2020) (65)
Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. (2018) (64)
Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment. (2016) (64)
Association of Air Pollution Exposures With High-Density Lipoprotein Cholesterol and Particle Number: The Multi-Ethnic Study of Atherosclerosis (2017) (61)
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). (2012) (58)
Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. (2017) (57)
The fat-mass and obesity-associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women. (2010) (57)
Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment. (2019) (54)
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The JUPITER Trial (2015) (54)
A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study. (2013) (53)
Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins (2017) (52)
Assessment of Risk Factors and Biomarkers Associated With Risk of Cardiovascular Disease Among Women Consuming a Mediterranean Diet (2018) (51)
High-Density Lipoprotein Particle Subclass Heterogeneity and Incident Coronary Heart Disease (2014) (51)
Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women’s Health Initiative (2018) (50)
Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation: A Mendelian Randomization Study (2019) (50)
Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER). (2014) (49)
Directed Non-targeted Mass Spectrometry and Chemical Networking for Discovery of Eicosanoids and Related Oxylipins. (2018) (48)
Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. (2015) (48)
Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA‐3 TriaL (VITAL) (2020) (47)
The vitamin D for COVID-19 (VIVID) trial: A pragmatic cluster-randomized design (2020) (47)
Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. (2016) (47)
Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. (2021) (47)
Circulating N‐Linked Glycoprotein Side‐Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial (2016) (44)
Dietary Intakes and Circulating Concentrations of Branched-Chain Amino Acids in Relation to Incident Type 2 Diabetes Risk Among High-Risk Women with a History of Gestational Diabetes Mellitus. (2018) (44)
Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial. (2021) (43)
Nonfasting for Routine Lipid Testing: From Evidence to Action. (2016) (43)
Markers of Inflammation and Incident Breast Cancer Risk in the Women’s Health Study (2018) (40)
Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm. (2019) (40)
Association of High-Density Lipoprotein Cholesterol With Incident Cardiovascular Events in Women, by Low-Density Lipoprotein Cholesterol and Apolipoprotein B100 Levels (2011) (39)
Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). (2016) (38)
Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20 years: The Women's Health Study. (2017) (38)
Lipoprotein subclass abnormalities and incident hypertension in initially healthy women. (2011) (38)
Biomarkers for prediction of cardiovascular events. (2007) (37)
Statistical Workflow for Feature Selection in Human Metabolomics Data (2019) (37)
Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice. (2016) (36)
Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence (2020) (35)
Thyroid and Cardiovascular Disease Research Agenda for Enhancing Knowledge, Prevention, and Treatment. (2019) (35)
Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text (2019) (32)
Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). (2014) (28)
A national interactive web-based physical activity intervention in women, evaluation of the american heart association choose to move program 2006-2007. (2012) (27)
Supplementation with Vitamin D and/or Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization: VITAL-Heart Failure. (2019) (26)
Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)". (2014) (26)
Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality (2016) (26)
Fasting for lipid testing: is it worth the trouble?: comment on "fasting time and lipid levels in a community-based population". (2012) (25)
Fasting for lipid testing: Is it worth the trouble? (2012) (25)
Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia—a randomized controlled feeding trial (2021) (25)
Clinical decisions. The guidelines battle on starting statins. (2014) (25)
Altered branched chain amino acid metabolism: toward a unifying cardiometabolic hypothesis (2018) (24)
Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. (2022) (23)
GlycA, a novel inflammatory marker, is associated with subclinical coronary disease (2018) (22)
Impact of Subclinical Hypothyroidism on Cardiometabolic Biomarkers in Women (2017) (20)
Gender-Specific Prediction of Cardiac Disease: Importance of Risk Factors and Exercise Variables (2006) (20)
Effects of statins on the immunoglobulin G glycome. (2017) (20)
Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come? (2016) (20)
Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. (2019) (19)
Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study (2014) (19)
Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: The Multi‐Ethnic Study of Atherosclerosis (2018) (19)
Re-assessing the role of non-fasting lipids; a change in perspective. (2016) (19)
Circulating branched-chain amino acids and long-term risk of obesity-related cancers in women (2020) (18)
The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: The Multi-Ethnic Study of Atherosclerosis. (2019) (18)
Serum 25-hydroxyvitamin D in the VITamin D and OmegA-3 TriaL (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment. (2019) (17)
Association of the Mediterranean Diet With Onset of Diabetes in the Women’s Health Study (2020) (17)
Concordance of Cardiovascular Risk Factors and Behaviors in a Multiethnic US Nationwide Cohort of Married Couples and Domestic Partners (2020) (17)
Aspirin therapy in primary prevention: comment on "effect of aspirin on vascular and nonvascular outcomes". (2012) (16)
Marine n-3 fatty acids and prevention of cardiovascular disease and cancer (2019) (16)
GlycA, a Novel Inflammatory Marker and Its Association With Peripheral Arterial Disease and Carotid Plaque: The Multi-Ethnic Study of Atherosclerosis (2019) (15)
Abstract 10170: Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (2013) (14)
Group IIA Secretory Phospholipase A2, Vascular Inflammation, and Incident Cardiovascular Disease. (2019) (14)
Clinical Characteristics and Severity of COVID-19 Disease in Patients from Boston Area Hospitals (2020) (13)
Association of High‐Density Lipoprotein‐Cholesterol Versus Apolipoprotein A‐I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer‐Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study (2017) (13)
Glycosylation Signatures of Inflammation Identify Cardiovascular Risk: Some Glyc It Hot. (2016) (13)
Premature Myocardial Infarction in the Middle East and North Africa: Rationale for the Gulf PREVENT Study (2020) (13)
Hypothyroidism and kidney function - a Mendelian Randomization study. (2020) (13)
Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review (2019) (13)
Habitual Fish Consumption, n‐3 Fatty Acids, and Nuclear Magnetic Resonance Lipoprotein Subfractions in Women (2020) (13)
SARS2 simplified scores to estimate risk of hospitalization and death among patients with COVID-19 (2020) (12)
Providing patients with global cardiovascular risk information: is knowledge power? (2010) (12)
Quantum approximate Bayesian computation for NMR model inference (2019) (12)
Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement (2019) (11)
Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and OmegA-3 TriaL. (2020) (11)
Branched-Chain Amino Acids and Risk of Breast Cancer (2020) (11)
Risk factors associated with premature myocardial infarction: a systematic review protocol (2019) (11)
Association of Plasma Branched-Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women (2021) (10)
Discordance of LDL Cholesterol with Alternative LDL-Related Measures and Future Coronary Events (2013) (10)
Cholesterol Insights and Controversies From the UK Biobank Study. (2019) (10)
Exercise-Induced Ventricular Ectopy and Cardiovascular Mortality in Asymptomatic Individuals (2021) (10)
Genetic associations with lipoprotein subfraction measures differ by ethnicity in the multi-ethnic study of atherosclerosis (MESA) (2017) (9)
Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization. (2022) (9)
One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL) (2020) (9)
Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial (2020) (9)
Clinical Implications of Discordance Between LDL Cholesterol and LDL Particle Number (2011) (8)
Abstract 17731: Protein Glycan Side-Chains, Rosuvastatin Therapy, and Incident Vascular Events: An Analysis from the JUPITER Trial (2014) (8)
Gene-Based Elevated Triglycerides and Type 2 Diabetes Mellitus Risk in the Women’s Genome Health Study (2019) (8)
Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. (2019) (8)
Risk Factors for Premature Myocardial Infarction: A Systematic Review and Meta-analysis of 77 Studies (2021) (8)
Effects of Vitamin D3 Supplementation on Body Composition in the VITamin D and OmegA-3 TriaL (VITAL) (2021) (8)
Adiposity and Genetic Factors in Relation to Triglycerides and Triglyceride-Rich Lipoproteins in the Women's Genome Health Study. (2018) (8)
Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach (2018) (7)
Lifelong low Lp(a) levels: genetics give a green light? (2021) (7)
HDL cholesterol, size, particle number, and residual vascular risk after potent statin therapy: the JUPITER trial (2013) (7)
Association of HDL Cholesterol with Incident Cardiovascular Events by LDL Cholesterol and Apolipoprotein B100 in Women (2011) (7)
Are there sex differences in acute coronary syndrome presentation?: a guide through the maze. (2013) (7)
Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): An Overlooked Form of Hypoglycemia in Clinical Practice (2018) (7)
SARS2 simplified scores to estimate risk of hospitalization and death among patients with COVID-19 (2021) (7)
Association of obesity indices with in-hospital and 1-year mortality following acute coronary syndrome (2020) (7)
What's different about women's health? (2014) (7)
Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial (2022) (7)
Marine Omega-3 Fatty Acids and Cardiovascular Disease Prevention: Seeking Clearer Water. (2021) (6)
Elevated C-reactive protein in high-risk asymptomatic individuals is strongly associated with the metabolic syndrome (2003) (6)
Probabilistic identification of saccharide moieties in biomolecules and their protein complexes (2020) (6)
Red blood cell fatty acid patterns from 7 countries: Focus on the Omega-3 index. (2022) (6)
Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein–Related Measures (2015) (6)
Value of reserve pulse pressure in improving the risk stratification of patients with normal myocardial perfusion imaging. (2013) (6)
Coronary artery disease in postmenopausal women (2001) (6)
Stability and reproducibility of proteomic profiles in epidemiological studies: comparing the Olink and SOMAscan platforms (2022) (6)
Glucose levels in the normal range predict incident diabetes in families with premature coronary heart disease. (2006) (6)
The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering (2018) (6)
Abstract 18807: Novel Protein Glycan Derived Biomarker is Associated With Incident Diabetes (2013) (6)
Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease (2022) (5)
Longitudinal Changes in Cholesterol Efflux Capacities in Patients With Coronary Artery Disease Undergoing Lifestyle Modification Therapy (2018) (5)
Aspirin therapy in women: back to the ABCs. (2009) (5)
CHAPTER 13 – Use of High-Sensitivity C-Reactive Protein for Risk Assessment (2009) (5)
Proceedings of the Ninth HDL (High-Density Lipoprotein) Workshop: Focus on Cardiovascular Disease. (2019) (5)
Glycosylation and Cardiovascular Diseases. (2021) (5)
Focus on Cardiovascular Disease (2019) (5)
Association of High‐Density Lipoprotein Particles and High‐Density Lipoprotein Apolipoprotein C‐III Content With Cardiovascular Disease Risk According to Kidney Function: The Multi‐Ethnic Study of Atherosclerosis (2019) (5)
Fasting for Laboratory Tests Poses a High Risk of Hypoglycemia in Patients with Diabetes: A Pilot Prevalence Study in Clinical Practice (2016) (5)
Fasting status and metabolic health in relation to plasma branched chain amino acid concentrations in women. (2020) (4)
Marine n-3 Fatty Acids and Vitamin D Supplementation and Primary Prevention. Reply. (2019) (4)
Certain cardiac risk factors predict risk factor interventions and influence communication between physicians and patients. (2000) (4)
Effects of thyroid function on hemostasis, coagulation, and fibrinolysis: a Mendelian Randomization study. (2021) (4)
Is it time to abandon fasting for routine lipid testing? (2017) (4)
Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subfractions (2021) (4)
Association of Physical Activity With Bioactive Lipids and Cardiovascular Events (2022) (4)
Are advanced lipoprotein testing and subfractionation clinically useful (2009) (3)
Reply to Letters Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)". (2015) (3)
Perspectives on the Changing Landscape of Measuring Cardiovascular Risk Related to LDL. (2019) (3)
Lp(a)'s Odyssey: Should We Measure Lp(a) Post-ACS and What Should We Do With the Results? (2020) (3)
A Prospective Comparison of NMR-Measured LDL Particle Number, Apolipoprotein B100, and Standard Lipids with Incident CHD in 27,673 Initially Healthy Women (2007) (3)
Multivitamins in the prevention of cancer and cardiovascular disease: The COSMOS randomized clinical trial. (2022) (3)
Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo. (2022) (3)
Nonfasting Lipids for All Patients? (2020) (3)
ATHEROGENIC LIPOPROTEIN PARTICLE SUBCLASSES AND RESIDUAL CARDIOVASCULAR RISK: AN ANALYSIS OF THE JUPITER TRIAL (2015) (3)
Sugar-Sweetened Beverage Consumption May Modify Associations Between Genetic Variants in the CHREBP (Carbohydrate Responsive Element Binding Protein) Locus and HDL-C (High-Density Lipoprotein Cholesterol) and Triglyceride Concentrations (2021) (3)
Whom to Treat for Primary Prevention of Atherosclerotic Cardiovascular Disease: The Aspirin Dilemma. (2022) (2)
Misperceptions and management of risk: Ongoing challenges in women's cardiovascular health. (2021) (2)
A NOVEL BIOMARKER OF CIRCULATING GLYCOPROTEINS AND CARDIOVASCULAR AND ALL-CAUSE MORTALITY AMONG 39,521 INITIALLY HEALTHY ADULTS (2015) (2)
Sugar-sweetened Beverage Consumption May Modify Associations between Genetic Variants in the CHREBP Locus and HDL-C and TG Concentrations. (2021) (2)
Abstract 1462: Association of HDL Cholesterol and Apolipoprotein A-1 With Incident CVD Across Levels of LDL Cholesterol in 27,748 Women (2009) (2)
Abstract 16055: Lipoprotein Subclasses, Size, and Statin-Associated Incident Diabetes: An Analysis From the JUPITER Trial (2014) (2)
Biphasic Pulmonary Regurgitation (2009) (2)
Fibroblast growth factor-21 levels in metabolic syndrome: Another instrument in a widening tool belt? (2019) (2)
Association of Body Weight With Response to Vitamin D Supplementation and Metabolism (2023) (2)
University of Groningen Physical Activity Attenuates the Influence of FTO Variants on Obesity Risk (2011) (2)
Abstract 9882: Post-Exercise Blood Pressure Predicts Future Cardiovascular Mortality in Asymptomatic Individuals (2012) (2)
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees (2022) (2)
SAFETY PROFILE OF STATIN-TREATED PATIENTS WITH LDL-C < 30MG/DL (2012) (2)
Moving beyond mean glycemia: 1,5-anhydroglucitol and microvascular complications of diabetes. (2014) (2)
Identifying risk factors for premature CAD (2001) (2)
Discovery and Refinement Supplementary (2015) (1)
Abstract 17959: Paradoxical Association of LDL Measures With the Risk of Incident Atrial Fibrillation (2013) (1)
Sugar-sweetened Beverage Consumption and Plasma Lipoprotein Cholesterol, Apolipoprotein, and Lipoprotein Particle Size Concentrations in U.S. Adults. (2022) (1)
Non-fasting blood testing for lipid screening in children result in statistically significant, but not clinically significant, changes in lipid levels (2012) (1)
Residual risk in TNT (2012) (1)
Predicting Asthma Exacerbations from a Drop of Blood. (2017) (1)
The association of cardiovascular mortality with a first-degree family member history of different cardiovascular diseases (2021) (1)
Lifestyle InteractionWith FatMass and Obesity-Associated ( FTO ) Genotype and Risk of Obesity in Apparently Healthy U . S . Women (2011) (1)
Abstract 13479: Association of Plasma Branched Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women (2020) (1)
Statistical Methods and Workflow for Analyzing Human Metabolomics Data. (2017) (1)
Abstract P280: Revisiting CVD Risk Prediction Using Machine Learning Approaches: A Case Study (2020) (1)
The Metabolic Syndrome as a Cluster of Risk Factors (2017) (1)
Abstract 18502: Mass and Genetic Polymorphism of Group IIA Secretory Phospholipase A2, Rosuvastatin Therapy, and Risk of Cardiovascular Events: An Analysis From the JUPITER Trial (2015) (1)
Abstract 019: Modifiable Lifestyle Factors And Plasma Branched Chain Amino Acids: An Analysis Of N=19,472 US Women (2021) (1)
Probabilistic identification of saccharide moieties in biomolecules and their protein complexes (2020) (1)
Abstract 3936: Homocysteine Concentration, 5, 10-Methylenetetrahydrofolate Reductase 677C>T Gene Polymorphism, and Intake of Folate and B-Vitamins in 24,968 Asymptomatic Women (2006) (1)
Over-the-counter fish oil supplementation and pro-resolving and pro-inflammatory lipid mediators in rheumatoid arthritis. (2023) (1)
Exercise Treadmill Stress Testing With and Without Imaging (2011) (1)
Abstract 18720: HDL Particle Subclasses, Rosuvastatin Therapy, and Risk of Vascular Events: An Analysis From the JUPITER Trial (2015) (1)
The Curious Case of Synergy between Lipoprotein (a), Coronary Calcification, and Cardiovascular Disease Risk. (2022) (1)
The exercise tolerance test predicts future cardiovascular and all-cause death in asymptomatic women (2002) (1)
Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular American Academy of Family Physicians; American Association of Prevention of Cardiovascular Disease): Developed in Collaboration With the Measures (Writing Committee to Develop Performance Measures for Primary Cardiology Foun (2009) (1)
Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial (2022) (1)
Effects of a Low-Carbohydrate Diet on Cardiometabolic Risk Factors During Weight-Loss Maintenance: A Randomized Controlled Feeding Trial (2020) (1)
Abstract 20653: Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort of Women: The Women’s Health Initiative (2017) (1)
The Inflammation Biomarker GlycA Reflects Plasma N-Glycan Branching. (2022) (1)
Blood pressure and risk of developing type 2 diabetes mellitus : The Women's Health Study. Commentary (2007) (1)
Abstract 18739: Novel Protein Glycan Derived Marker of Systemic Inflammation is Associated With Incident Cardiovascular Disease (2013) (1)
Response to Letter Regarding Article, “Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women” (2009) (1)
Assessing the dyslipidemias: to fast or not to fast? (2021) (1)
Mediterranean Diet Social Network Impact along 11 Years in the Major US Media Outlets: Thematic and Quantitative Analysis Using Twitter (2022) (1)
Zareen Farukhi and Samia Mora and Potent Low-Density Lipoprotein Lowering The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing (2017) (0)
Aspirin for the Primary Prevention of Atherosclerotic Cardiovascular Disease in Women. (2022) (0)
Risk and Benefit Information and Use of Aspirin-Reply. (2017) (0)
Abstract 17400: Using Electronic Health Records for Predicting Hospitalization of COVID-19 Patients in Massachusetts (2020) (0)
Abstract P040: GlycA, a Novel Inflammatory Marker, and Subclinical Coronary Atherosclerosis in the Multicenter AIDS Cohort Study (MACS) (2018) (0)
Genetic associations with lipoprotein subfraction measures differ by ethnicity in the multi-ethnic study of atherosclerosis (MESA) (2017) (0)
What Are Advanced Lipoprotein Tests Often Used for in Clinical Practice ? (2009) (0)
Identification and targeting of genes in atherosclerosis (2017) (0)
Abstract 17662: Nonfasting Compared With Fasting Lipids for Predicting Major Coronary Events in ASCOT-LLA (2016) (0)
Abstract 18416: Discordance Between nonHDLc and Lipoprotein Particle Concentration (apoB and LDLp) in Relation to Future Coronary Events in Women (2015) (0)
Abstract 11184: High Concordance of Non-ideal Cardiovascular Health Metrics in a Nation-wide Study of 5,364 Spouse-pairs (2019) (0)
Abstract WP219: The Relationship of Low-Density Lipoprotein (LDL) Particle Number (LDL-P) and LDL Particle Size and Incident Stroke Events: The Multi-Ethnic Study of Atherosclerosis (2017) (0)
Effects of Vitamin D3 Supplementation on Cardiovascular and Cancer Outcomes by eGFR in VITAL (2022) (0)
Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease. (2022) (0)
EXERCISE-INDUCED VENTRICULAR ECTOPY AND FUTURE CARDIOVASCULAR DEATH IN ASYMPTOMATIC INDIVIDUALS: A 20-YEAR FOLLOW-UP OF THE LIPID RESEARCH CLINICS PREVALENCE STUDY (2021) (0)
Abstract 746: Branched-chain amino acids and risk of breast cancer by menopausal status in three large cohorts (2021) (0)
Abstract 37: Lipoprotein Subclasses and Incident Type 2 Diabetes in the Multi-Ethnic Study of Atherosclerosis (2014) (0)
Abstract 10909: LDL and HDL Particle vs. Cholesterol Concentration in Metabolic Syndrome and Diabetes for the Prediction of Coronary Heart Disease: The Multiethnic Study of Atherosclerosis (2015) (0)
ASSOCIATION BETWEEN SERUM CALCIUM AND COGNITIVE FUNCTION IN HEALTHY PEOPLE AGED 60 OR OLDER IN THE VITAL STUDY (2016) (0)
Social Determinants of Health and Mortality After Premature and Non-premature Acute Coronary Syndrome (2023) (0)
Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease-Reply. (2016) (0)
Abstract 5000: A Prospective Examination of the Association of Nuclear Magnetic Resonance Measured Lipoprotein Particles with Incident Hypertension in the Women's Health Study (2008) (0)
Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial (2022) (0)
P619Incident premature coronary heart disease in women: an analysis of 53 biomarkers from the Women's Health Study (2018) (0)
Does the presence of certain cardiac risk factors positively influence risk factor interventions (1998) (0)
Fish consumption, omega-3 fatty acids (n-3), and nmr lipoprotein subfractions in 26034 apparently healthy women (2015) (0)
193 COMPARISON OF THEORETICAL AND EXPERIMENTAL RELATIONSHIPS BETWEEN HDL SIZE AND THE RATIO OF HDL CHOLESTEROL (HDL-C) TO APOLIPOPROTEIN A-I (APOA-I) (2011) (0)
Abstract 16471: Lipoprotein(a) Cholesterol and Cardiovascular Events in the VITamin D and OmegA 3 TriaL (Vital) (2020) (0)
The Association of HDL-C vs Apolipoprotein A-I with Risk of Coronary Heart Disease (2017) (0)
Abstract 630: Lipoprotein Subclasses by Ion Mobility and First Cardiovascular Events: An Analysis of 11,227 Participants From the JUPITER Trial (2014) (0)
Abstract 13189: Effects of Marine Omega-3 Supplementation on Fatty Acids and Bioactive Lipids and Associations With Risk of Cardiovascular Disease: Secondary Analysis From the Randomized Vitamin D and Omega-3 Trial (VITAL) (2019) (0)
Patient-physician-medical record disagreement on cardiovascular risk factor management (1998) (0)
WiNN: Drift correction by white noise normalization for metabolomic studies (2020) (0)
Abstract 15658: Determinants of Residual Risk in 9,251 Secondary Prevention Patients Treated with High- versus Low-dose Statin Therapy: The Treating to New Targets (TNT) Study (2011) (0)
Routine Clinical Use Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for (2009) (0)
Echocardiography for cardiac surgery (2018) (0)
Adding Exercise Testing to Framingham Score for Cardiovascular Risk Assessment (2005) (0)
LDL PARTICLE SIZE : DOES IT MATTER ? (0)
Serum Vitamin D: Correlates of Baseline Concentration and Response to Supplementation in VITAL-DKD. (2021) (0)
CARDIOVASCULAR DISEASE MORTALITY AND ITS ASSOCIATION WITH PATERNAL, MATERNAL AND SIBLING HISTORY OF DISEASES AN 18-YEAR FOLLOW-UP STUDY (2021) (0)
Level of Exercise and Risk of Cardiovascular Disease—Reply (2004) (0)
Mediterranean diet social network impact along 11 years in the major US media outlets: Thematic and Quantitative Analysis using Twitter. (Preprint) (2020) (0)
LEISURE-TIME PHYSICAL ACTIVITY ASSOCIATES FAVORABLY WITH THE BIOACTIVE LIPIDOME AND RISK OF INCIDENT CVD EVENTS/ RESULTS FROM THE VITAMIN D AND OMEGA-3 TRIAL (VITAL) AND JUPITER TRIALS (2021) (0)
Sugar-Sweetened Beverage Consumption and Plasma Lipoprotein Cholesterol, Apolipoprotein, and Lipoprotein Particle Size Concentrations in US Adults (2022) (0)
From the EAS:* frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society (2023) (0)
Lipoprotein(A) Predicts Cardiovascular Events In Statin Outcome Trials: Pooled Analysis Of Seven Randomised Controlled Trials (2019) (0)
Background—It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with cardiovascular risk among patients who achieve very low levels of low-density lipoprotein cholesterol on statin therapy. It is also unknown whether (2013) (0)
Abstract B79: Novel protein glycan biomarker and future colorectal cancer (2016) (0)
Abstract 40: Score Based on Immunoglobulin G N-glycans for Cardiovascular Risk Prediction: Secondary Analysis of Two Randomized Trials of Primary and Secondary Prevention (2023) (0)
Abstract 11848: Biomarkers of Glucose-Insulin Homeostasis, Randomized Treatment With Omega-3 and Vitamin D Supplementation, and Incident Type 2 Diabetes: Prospective Analysis From the Vitamin D and Omega-3 Trial (VITAL) (2021) (0)
Abstract 20246: Impact of Subclinical Hypothyroidism on Lipid and Lipoprotein Subclasses (2014) (0)
Abstract 4023: Do Known Risk Factors Explain the Inverse Relation Between Physical Activity and Cardiovascular Disease Risk? (2006) (0)
Analyzing Mediterranean diet on Twitter: a 11-year analysis of tweets from the major US media outlets. (Preprint) (2020) (0)
W26 DISCORDANCE BETWEEN LDL CHOLESTEROL AND LDL PARTICLE CONCENTRATION IN RELATION TO INCIDENT CVD EVENTS IN 27673 WOMEN (2010) (0)
Response to letter regarding article, "High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy". (2014) (0)
Partitioning the Genetic Architecture of Plasma Lipoprotein(a) and Kringle IV Type 2 Repeats: Implications for Therapeutic Lowering. (2017) (0)
CLINICAL DETERMINANTS OF INCIDENT AORTIC STENOSIS IN STATIN–TREATED STABLE CORONARY PATIENTS (2013) (0)
Abstract 12828: Mediterranean Diet and Reduced Risk of Cardiovascular Disease: Potential Mediating Mechanisms (2018) (0)
High specificity and negative predictive value of exercise testing for long-term mortality in asymptomatic men (2002) (0)
Abstract 17747: Associations of Ideal Cardiovascular Health by AHA Life Simple 7 Criteria With N-Linked Glycoprotein Acetyl (GlycA), a Novel Inflammatory Marker: The Multi-Ethnic Study of Atherosclerosis (MESA) (2017) (0)
Abstract 16278: Discordant Lipid Phenotype and Other Determinants of Statin Response in the Pravastatin Inflammation/crp Evaluation (PRINCE) Trial (2020) (0)
CHOLESTEROL EFFLUX CAPACITY, HDL-PARTICLE NUMBER, AND INCIDENT CARDIOVASCULAR EVENTS: RESULTS FROM THE JUPITER TRIAL (2016) (0)
COMBINING MULTIPLE CARDIOVASCULAR RISK PREDICTION MODELS IMPROVES MODEL PERFORMANCE: A NOVEL FLEXIBLE FRAMEWORK APPROACH APPLIED TO A CONTEMPORARY AND DIVERSE EHR COHORT (2022) (0)
A Still-Ignored Cardiovascular Risk Factor-A History of Preeclampsia-Reply. (2021) (0)
1102 Fish oil supplementation and pro-inflammatory and pro-resolving lipid mediators in patients with and without systemic lupus erythematosus (2021) (0)
Abstract 11268: Fasting Low Density Lipoprotein Cholesterol (LDL-C) Levels Stratified by Fasting Time Do Not Have Significant Improvement in Prognostic Value versus Non-fasting LDL-C (2014) (0)
Errors in Equation and Modeling Parameter. (2016) (0)
Abstract P330: Effect of Randomized Omega-3 Treatment on Downstream Bioactive Lipids and Their Association With Incident Cardiovascular Disease Events: Metabolomic Studies of the Vital and Jupiter Trials (2023) (0)
Abstract P341: A Flexible, Interpretable Approach to Recalibrate Risk Prediction Models: Adapting the Pooled Cohorts Equation to a Local New England Contemporary Population (2023) (0)
Clinical determinants of incident aortic valve stenosis in patients treated with atorvastatin: results from three large randomized clinical trials (2013) (0)
Abstract 13310: Anti-Inflammatory HDL Function and Incident Cardiovascular/Death Events: A Secondary Analysis of the JUPITER Trial (2018) (0)
Left Ventricular Noncompaction/ Hypertrabeculation: Distinctive Entity or Abnormality, Frequently (2011) (0)
Abstract P260: Determinants of Statin Response: A Secondary Analysis of the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) (2020) (0)
Abstract P346: Novel Protein Glycan Derived Marker of Systemic Inflammation is Associated with Incident Coronary Heart Disease and Ischemic Stroke (2014) (0)
Abstract 13397: Determining the Optimal Cutpoint Value for the Diagnosis of Hypertriglyceridemia in the Nonfasting Population (2014) (0)
Abstract 17304: Web-Based 12-Week Activity Intervention (American Heart Association Choose to Move Program) Improved Compliance with Guideline Recommendations (2010) (0)
Abstract: 1470 SHOULD APOB OR LDL PARTICLE CONCENTRATION REPLACE STANDARD LIPIDS FOR PRIMARY PREVENTION OF CVD? (2009) (0)
Abstract 1093: A Prospective Comparison of NMR-Measured Large Versus Small LDL particles with Incident CHD in 27,673 Initially Healthy Women (2007) (0)
Association of modifiable lifestyle factors with plasma branched chain amino acid metabolites in women. (2022) (0)
A little more time around the track may go a long way: Implications of increasing moderate to vigorous physical activity in pre-adolescents. (2019) (0)
13-OR: Effects of Randomized Statin Therapy vs. Placebo on Plasma Branched-Chain Amino Acids (BCAAs) and Type 2 Diabetes (T2D) Risk: Secondary Analysis of the JUPITER Trial (2021) (0)
Risk of type 2 diabetes mellitus in those with hypertension: reply (2008) (0)
Reply to Ramírez PC and Diaz-Quijano FA (AJCN-D-22-00631). (2022) (0)
Mediterranean Diet And Reduced Risk Of Diabetes: Potential Mediating Mechanisms (2019) (0)
Abstract 2178: Does Lifestyle Modify the Genetic Risk of Obesity? An Association Study of Lifestyle Interactions With FTO Genotype in 21,675 Caucasian Women (2009) (0)
Abstract 1426: Rosuvastatin for the Primary Prevention of Cardiovascular Events in Women With Elevated hsCRP and Low LDLC: Sex-Specific Outcomes From the JUPITER Trial (2009) (0)
Abstract 14943: Comparison of Fasting and Nonfasting Lipoprotein Subfractions and Size in 13,460 Apparently Healthy Individuals (2017) (0)
RESIDUAL RISK AND ON-STATIN REDUCTIONS IN TRIGLYCERIDES, REMNANT CHOLESTEROL, AND VLDL LIPOPROTEINS: AN ANALYSIS FROM THE JUPITER TRIAL (2016) (0)
Abstract P021: Performance Of Pooled Cohort Equations And MESA Risk Score Across Race/Ethnicity And Socioeconomic Status To Estimate 10-year Cardiovascular Risk In Diverse New England Cohort (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Samia Mora?

Samia Mora is affiliated with the following schools: